These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27884504)

  • 1. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
    Rizwan SB; Vernall AJ
    BMJ; 2017 Mar; 356():j1195. PubMed ID: 28314708
    [No Abstract]   [Full Text] [Related]  

  • 7. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 9. Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age.
    Griffiths P; Evans-Brown M; Sedefov R
    Addiction; 2013 Oct; 108(10):1700-3. PubMed ID: 23865891
    [No Abstract]   [Full Text] [Related]  

  • 10. New psychoactive substances detected at the New Zealand border, 2014-2018.
    Johnson CS; Copp BR; Lewis A
    Drug Test Anal; 2019 Feb; 11(2):341-346. PubMed ID: 30346116
    [No Abstract]   [Full Text] [Related]  

  • 11. New psychoactive substances: issues about the new approach from New Zealand government.
    von Diemen L
    Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704
    [No Abstract]   [Full Text] [Related]  

  • 12. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract]   [Full Text] [Related]  

  • 13. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in new psychoactive substance use disorders following legislation targeting headshops: Evidence from national addiction treatment data.
    Smyth BP; Lyons S; Cullen W
    Drug Alcohol Rev; 2017 Sep; 36(5):609-617. PubMed ID: 28419577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worldwide legislative challenges related to psychoactive drugs.
    Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
    Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal Approaches to New Psychoactive Substances: First Empirical Findings.
    van Amsterdam J; Burgess N; van den Brink W
    Eur Addict Res; 2023; 29(5):363-372. PubMed ID: 37557091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
    Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
    J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia.
    Burns L; Roxburgh A; Bruno R; Van Buskirk J
    Drug Test Anal; 2014; 6(7-8):840-5. PubMed ID: 24574080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.